Nicholas DeVito, Erica Gray, Daniel Schrum, Scott Antonia
{"title":"Addressing Common Medications That Influence Immunotherapy Response in Solid Tumors.","authors":"Nicholas DeVito, Erica Gray, Daniel Schrum, Scott Antonia","doi":"10.1200/JCO-25-01811","DOIUrl":"https://doi.org/10.1200/JCO-25-01811","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2501811"},"PeriodicalIF":41.9,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145917725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marieke J Hollestelle, Rob Kessels, Peter M van de Ven, Rieke van der Graaf
{"title":"Ethics of Backfilling in Early-Phase Oncology Trials.","authors":"Marieke J Hollestelle, Rob Kessels, Peter M van de Ven, Rieke van der Graaf","doi":"10.1200/JCO-25-02005","DOIUrl":"https://doi.org/10.1200/JCO-25-02005","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2502005"},"PeriodicalIF":41.9,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145917807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lisa K Hicks,Hans J Messersmith,Samer Al Hadidi,Rahul Banerjee,Benjamin A Derman,Shaji Kumar,Tanya M Wildes,Susan Bal,Sita Bhella,Cynthia Chmielewski,Caitlin Costello,Raetasha Dabney,Monique Hartley-Brown,Alan Langerak,Brea Lipe,Thomas Martin,Arleigh McCurdy,Hira Mian,Eloisa Riva,Rahul Seth,Latha Subramanian,Joseph Mikhael
PURPOSETo provide updated guidance regarding the therapy for multiple myeloma.METHODSASCO and Ontario Health (Cancer Care Ontario) convened a joint Expert Panel and conducted an updated systematic review of the literature.RESULTSThe updated review identified a total of 161 relevant randomized trials.UPDATED RECOMMENDATIONSDaratumumab therapy may be offered to patients with high-risk smoldering myeloma. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as initial therapy for transplant eligible patients. They should also be offered at least lenalidomide maintenance, with or without daratumumab, carfilzomib, and/or dexamethasone. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as therapy for suitable transplant-ineligible patients. Patients with relapsed or refractory multiple myeloma should be offered triplet therapy or T-cell redirecting therapies according to a set of recommended principles.Additional information is available at www.asco.org/hematologic-malignancies-guidelines.
{"title":"Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.","authors":"Lisa K Hicks,Hans J Messersmith,Samer Al Hadidi,Rahul Banerjee,Benjamin A Derman,Shaji Kumar,Tanya M Wildes,Susan Bal,Sita Bhella,Cynthia Chmielewski,Caitlin Costello,Raetasha Dabney,Monique Hartley-Brown,Alan Langerak,Brea Lipe,Thomas Martin,Arleigh McCurdy,Hira Mian,Eloisa Riva,Rahul Seth,Latha Subramanian,Joseph Mikhael","doi":"10.1200/jco-25-02587","DOIUrl":"https://doi.org/10.1200/jco-25-02587","url":null,"abstract":"PURPOSETo provide updated guidance regarding the therapy for multiple myeloma.METHODSASCO and Ontario Health (Cancer Care Ontario) convened a joint Expert Panel and conducted an updated systematic review of the literature.RESULTSThe updated review identified a total of 161 relevant randomized trials.UPDATED RECOMMENDATIONSDaratumumab therapy may be offered to patients with high-risk smoldering myeloma. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as initial therapy for transplant eligible patients. They should also be offered at least lenalidomide maintenance, with or without daratumumab, carfilzomib, and/or dexamethasone. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as therapy for suitable transplant-ineligible patients. Patients with relapsed or refractory multiple myeloma should be offered triplet therapy or T-cell redirecting therapies according to a set of recommended principles.Additional information is available at www.asco.org/hematologic-malignancies-guidelines.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"98 1","pages":"JCO2502587"},"PeriodicalIF":45.3,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kevin T Liou,Joke Bradt,M Beatriz Currier,Raymond Baser,Katherine Panageas,Jodi MacLeod,Desiree Walker,Susan Q Li,Ana Maria Lopez,Kelly McConnell,Jun J Mao
PURPOSEAnxiety is prevalent, disruptive, and undertreated among cancer survivors. Cognitive behavioral therapy (CBT) is the first-line treatment, but not all individuals have access, respond to treatment, or prefer this option because of stigma. Music therapy is effective for short-term anxiety reduction, but it is unknown whether it is noninferior to first-line CBT for long-term anxiety reduction.METHODSThis comparative effectiveness trial randomly assigned English- or Spanish-speaking cancer survivors to seven weekly telehealth sessions of music therapy or CBT. The coprimary end points were changes in the Hospital Anxiety and Depression Scale (HADS) anxiety score at weeks 8 and 26. The noninferiority margin was 0.35 standard deviations, informed by a minimal clinically important difference (MCID) of 1.7 points. Secondary outcomes included fatigue, depression, insomnia, pain, cognitive dysfunction, and health-related quality of life.RESULTSAmong N = 300 patients, 74.7% was female, 76.5% was White, and 19.0% was Hispanic. At week 8, the mean change in HADS anxiety score was -3.12 (95% CI, -3.59 to -2.65) in music therapy and -2.97 (95% CI, -3.45 to -2.50) in CBT; the between-group difference was -0.15 (95% CI, -0.78 to 0.49), within the noninferiority margin of 1.20 (P < .001). At week 26, the mean change was -3.31 (95% CI, -3.78 to -2.85) in music therapy and -3.00 (95% CI, -3.47 to -2.53) in CBT; the between-group difference was -0.31 (95% CI, -0.95 to 0.32), within the noninferiority margin of 1.28 (P < .001). Both groups produced anxiety reductions exceeding the MCID and showed similar improvements in secondary outcomes.CONCLUSIONMusic therapy is noninferior to CBT for anxiety in cancer survivors. Both telehealth interventions produced clinically meaningful, durable improvements in anxiety.
{"title":"Music Therapy Versus Cognitive Behavioral Therapy via Telehealth for Anxiety in Cancer Survivors: A Randomized Clinical Trial.","authors":"Kevin T Liou,Joke Bradt,M Beatriz Currier,Raymond Baser,Katherine Panageas,Jodi MacLeod,Desiree Walker,Susan Q Li,Ana Maria Lopez,Kelly McConnell,Jun J Mao","doi":"10.1200/jco-25-00726","DOIUrl":"https://doi.org/10.1200/jco-25-00726","url":null,"abstract":"PURPOSEAnxiety is prevalent, disruptive, and undertreated among cancer survivors. Cognitive behavioral therapy (CBT) is the first-line treatment, but not all individuals have access, respond to treatment, or prefer this option because of stigma. Music therapy is effective for short-term anxiety reduction, but it is unknown whether it is noninferior to first-line CBT for long-term anxiety reduction.METHODSThis comparative effectiveness trial randomly assigned English- or Spanish-speaking cancer survivors to seven weekly telehealth sessions of music therapy or CBT. The coprimary end points were changes in the Hospital Anxiety and Depression Scale (HADS) anxiety score at weeks 8 and 26. The noninferiority margin was 0.35 standard deviations, informed by a minimal clinically important difference (MCID) of 1.7 points. Secondary outcomes included fatigue, depression, insomnia, pain, cognitive dysfunction, and health-related quality of life.RESULTSAmong N = 300 patients, 74.7% was female, 76.5% was White, and 19.0% was Hispanic. At week 8, the mean change in HADS anxiety score was -3.12 (95% CI, -3.59 to -2.65) in music therapy and -2.97 (95% CI, -3.45 to -2.50) in CBT; the between-group difference was -0.15 (95% CI, -0.78 to 0.49), within the noninferiority margin of 1.20 (P < .001). At week 26, the mean change was -3.31 (95% CI, -3.78 to -2.85) in music therapy and -3.00 (95% CI, -3.47 to -2.53) in CBT; the between-group difference was -0.31 (95% CI, -0.95 to 0.32), within the noninferiority margin of 1.28 (P < .001). Both groups produced anxiety reductions exceeding the MCID and showed similar improvements in secondary outcomes.CONCLUSIONMusic therapy is noninferior to CBT for anxiety in cancer survivors. Both telehealth interventions produced clinically meaningful, durable improvements in anxiety.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"105 1","pages":"JCO2500726"},"PeriodicalIF":45.3,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A reflection by @SondosZayedMD on the unexpected power of saying "I don't know"-and how honest uncertainty can deepen trust, guide care, and create space for what truly matters in oncology. #JCO @JCO_ASCO.
{"title":"The Power of \"I Don't Know\".","authors":"Sondos Zayed","doi":"10.1200/jco-25-02489","DOIUrl":"https://doi.org/10.1200/jco-25-02489","url":null,"abstract":"A reflection by @SondosZayedMD on the unexpected power of saying \"I don't know\"-and how honest uncertainty can deepen trust, guide care, and create space for what truly matters in oncology. #JCO @JCO_ASCO.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"13 1","pages":"JCO2502489"},"PeriodicalIF":45.3,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Robert J Hayashi, Stuart S Winter, Kimberly P Dunsmore, Meenakshi Devidas, Zhiguo Chen, Brent L Wood, Michelle L Hermiston, David T Teachey, Sherrie L Perkins, Rodney R Miles, Elizabeth A Raetz, Mignon L Loh, Naomi J Winick, William L Carroll, Stephen P Hunger, Megan S Lim, Thomas G Gross, Catherine M Bollard
{"title":"Erratum: Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.","authors":"Robert J Hayashi, Stuart S Winter, Kimberly P Dunsmore, Meenakshi Devidas, Zhiguo Chen, Brent L Wood, Michelle L Hermiston, David T Teachey, Sherrie L Perkins, Rodney R Miles, Elizabeth A Raetz, Mignon L Loh, Naomi J Winick, William L Carroll, Stephen P Hunger, Megan S Lim, Thomas G Gross, Catherine M Bollard","doi":"10.1200/JCO-25-02779","DOIUrl":"https://doi.org/10.1200/JCO-25-02779","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2502779"},"PeriodicalIF":41.9,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145906052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Therapeutic Considerations in Early-Stage, Estrogen Receptor-Positive, BRCA-Associated Breast Cancer.","authors":"Susan M Domchek","doi":"10.1200/jco-25-02428","DOIUrl":"https://doi.org/10.1200/jco-25-02428","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"63 1","pages":"JCO2502428"},"PeriodicalIF":45.3,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145903670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-25DOI: 10.1200/JCO-25-00991
Trisha K Paul
{"title":"Are You Bereaved?","authors":"Trisha K Paul","doi":"10.1200/JCO-25-00991","DOIUrl":"10.1200/JCO-25-00991","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"66-67"},"PeriodicalIF":41.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145604448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-21DOI: 10.1200/JCO-25-02336
Rina K Yadav, Kathy D Miller
{"title":"Carboplatin for Premenopausal Triple-Negative Breast Cancer: Time to Rethink the Neoadjuvant Standard?","authors":"Rina K Yadav, Kathy D Miller","doi":"10.1200/JCO-25-02336","DOIUrl":"10.1200/JCO-25-02336","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"1-4"},"PeriodicalIF":41.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-20DOI: 10.1200/JCO-25-02667
Franck Morschhauser, Gilles Salles, Laurie H Sehn, Alex F Herrera, Jonathan W Friedberg, Marek Trněný, Georg Lenz, Jeff P Sharman, Charles Herbaux, John M Burke, Matthew Matasar, Graham P Collins, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Antonio Pinto, Shinya Rai, Koji Izutsu, Richard Greil, Larysa Mykhalska, Juan M Bergua-Burgués, Matthew C Cheung, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta, Jyh-Pyng Gau, Yanwen Jiang, Bruce McCall, Saibah Chohan, Matthew Sugidono, Mark Yan, Connie Lee Batlevi, Hervé Tilly, Christopher R Flowers
{"title":"Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.","authors":"Franck Morschhauser, Gilles Salles, Laurie H Sehn, Alex F Herrera, Jonathan W Friedberg, Marek Trněný, Georg Lenz, Jeff P Sharman, Charles Herbaux, John M Burke, Matthew Matasar, Graham P Collins, Neha Mehta-Shah, Lucie Oberic, Adrien Chauchet, Wojciech Jurczak, Yuqin Song, Antonio Pinto, Shinya Rai, Koji Izutsu, Richard Greil, Larysa Mykhalska, Juan M Bergua-Burgués, Matthew C Cheung, Ho-Jin Shin, Greg Hapgood, Eduardo Munhoz, Pau Abrisqueta, Jyh-Pyng Gau, Yanwen Jiang, Bruce McCall, Saibah Chohan, Matthew Sugidono, Mark Yan, Connie Lee Batlevi, Hervé Tilly, Christopher R Flowers","doi":"10.1200/JCO-25-02667","DOIUrl":"10.1200/JCO-25-02667","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"71"},"PeriodicalIF":41.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145564276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：